Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity
- 30 November 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (23), 8996-9002
- https://doi.org/10.1158/0008-5472.can-09-2915
Abstract
Docetaxel is one of the most widely used anticancer drugs. A major problem with docetaxel treatment, however, is the considerable interpatient variability in docetaxel exposure. Another disadvantage of the drug is that it has a very low oral bioavailability and can therefore only be administered i.v. The drug-metabolizing enzyme cytochrome P450 3A (CYP3A) and the drug transporter P-glycoprotein (P-gp; MDR1) are considered to be major determinants of docetaxel pharmacokinetics. It has been hypothesized that CYP3A and P-gp work synergistically in limiting the systemic exposure to many orally ingested drugs. However, it has been difficult to examine this interplay in vivo. We therefore generated mice lacking all CYP3A and P-gp genes. Although missing two primary detoxification systems, Cyp3a/Mdr1a/1b−/− mice are viable, fertile, and without spontaneous abnormalities. When orally challenged with docetaxel, a disproportionate (>70-fold) increase in systemic exposure was observed compared with the increases in single Cyp3a−/− (12-fold) or Mdr1a/1b−/− (3-fold) mice. Unexpectedly, although CYP3A and P-gp collaborated extremely efficiently in lowering docetaxel exposure, their individual efficacy was not dependent on activity of the other protein. On reflection, this absence of functional synergism makes biological sense, as synergism would conflict with a robust detoxification defense. Importantly, the disproportionate increase in docetaxel exposure in Cyp3a/Mdr1a/1b−/− mice resulted in dramatically altered and lethal toxicity, with severe intestinal lesions as a major cause of death. Simultaneous inhibition of CYP3A/P-gp might thus be a highly effective strategy to improve oral drug bioavailability but with serious risks when applied to drugs with narrow therapeutic windows. [Cancer Res 2009;69(23):8996–9002]Other Versions
This publication has 22 references indexed in Scilit:
- Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid TumorsClinical Cancer Research, 2009
- Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liverThe FASEB Journal, 2008
- Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C EnzymesMolecular Pharmacology, 2007
- Gut instincts: CYP3A4 and intestinal drug metabolismJCI Insight, 2007
- Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolismJCI Insight, 2007
- Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challengeCurrent Opinion in Pharmacology, 2006
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 2006
- Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometryBiomedical Chromatography, 2004
- Functional interaction of intestinal CYP3A4 and P‐glycoproteinFundamental & Clinical Pharmacology, 2004
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000